27 September 2024 Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector.
Shares of German pharma major Bayer were up 4.6% at 30.45 euros after it released positive early trial results for its Parkinson’s disease candidate. 27 September 2024
Shionogi said today that it has submitted a New Drug Application (NDA) in Japan for zuranolone, a treatment in development for major depressive disorder (MDD). 27 September 2024
CNS specialist Lundbeck has announced data from the TALISMAN natural history study, as well as additional data from the AMULET trial, of amlenetug, in multiple system atrophy (MSA) at the International Congress of Parkinson's Disease and Movement disorders in Philadelphia, USA. 27 September 2024
Repair Biotechnologies, a company developing therapies to reverse atherosclerotic plaque, has entered into a collaboration with Genevant Sciences, a specialist in nucleic acid delivery technology. 27 September 2024
China’s National Medical Products Administration (NMPA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). 27 September 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
US virology and immunology company Enanta Pharmaceuticals has given further weight to its claims to have the leading portfolio of potent respiratory syncytial virus (RSV) replication inhibitors 27 September 2024
Sage Therapeutics has announced that Biogen has terminated its partnership on the SAGE-324 program, following the recent failure of the drug in a Phase II study for the treatment of essential tremor. 27 September 2024
A US Food and Drug Administration advisory committee meeting has recommended restricting the use of PD-1 inhibitors, in a move which could affect blockbuster products such as Bristol Myers Squibb's Opdivo (nivolumab) and Merck & Co's Keytruda (pembrolizumab). 27 September 2024
The US Food and Drug Administration yesterday approved pharma major Bristol Myers Squibb’s Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment, particularly within China's burgeoning oncology sector. 27 September 2024
US drugmaker AbbVie has announced positive topline results from its pivotal Phase III TEMPO-1 trial for tavapadon as a monotherapy in early Parkinson's disease. 26 September 2024
Evaxion Biotech has entered into an option and license agreement with MSD (tradename of Merck & Co outside of the USA and Canada), for two pre-clinical vaccine candidates. 26 September 2024
Danish CNS specialist Lundbeck and US privately-held biotech Iambic Therapeutics today announced a strategic research collaboration to focus on discovery of a small molecule therapeutic for the treatment of migraine. 26 September 2024
The generics and biosimilars trade group, Medicines for Europe, has put out a strong message amid ongoing discussions on a European Union (EU) Critical Medicines Act. 26 September 2024
Pfizer (NYSE: PFE) has announced the withdrawal of Oxbryta (voxelotor), a treatment for sickle cell disease (SCD), from all global markets. 26 September 2024
Shares of US oncology specialist Nektar Therapeutics rose 5% to $17.10, after it announced a deal with two pharma majors to trial its investigational interleukin-15 (IL-15) receptor agonist NKTR-255. 24 September 2021
Pharmsynthez, one of Russia’s leading drugmakers, is planning to launch one of the largest productions of hormonal preparations in Russia, which will be located the city of Tyumen by November of the current year. 24 September 2021
Spanish drugmaker PharmaMar has announced its licensing partner, Specialised Therapeutics Asia (STA), has received provisional marketing approval for Zepzelca (lurbinectedin) by the Singapore Health Sciences Authority (HSA) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) who have progressed after prior platinum-containing chemotherapy. 24 September 2021
Japan’s Kyowa Kirin has provided new data for Crysvita (burosumab), revealing benefits for people with the rare metabolic bone disorder X-linked hypophosphatemia (XLH). 24 September 2021
Swiss pharma giant Roche today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20–24 September 2021. 24 September 2021
Otsuka Pharmaceutical company Astex Pharmaceuticals has provided new Phase III data from the ASCERTAIN trial of Inqovi (decitabine/cedazuridine). 24 September 2021
R-Pharm, one of Russia’s leading drugmakers, has started the production of a vaccine against COVID-19 under a license from Oxford University and UK pharma major AstraZeneca, according to recent statements made by some Russian state officials and local media reports. 24 September 2021
The aim of the US Food and Drug Administration’s Accelerated Approval Program (AAP) is to expedite the development of new therapies that address an unmet need in the treatment of serious diseases.1 However, recent controversies regarding AAP drugs have brought the program under severe scrutiny. We discuss the pros and cons of the program and how they impact its future. 24 September 2021
UK biotech Immunocore Holdings has announced that data from a Phase III trial comparing tebentafusp with investigator’s choice in first-line metastatic uveal melanoma (mUM) has been published in The New England Journal of Medicine (NEJM). 23 September 2021
The World Health Organization's Director General Tedros Adhanom Ghebreyesus has thanked India's Minister Mansukh Mandaviya for announcing that India will resume crucial COVID-19 vaccine shipments to COVAX in October. 23 September 2021
US biotech Novavax and its partner the Serum Institute of India today announced a regulatory submission to the World Health Organization (WHO) for emergency use listing (EUL) of Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine candidate with Matrix-M adjuvant. 23 September 2021
China’s Worg Pharmaceuticals (Hangzhou) has entered into an asset purchase agreement to acquire Belgian biotech’s Apitope International’s proprietary platform and therapeutic pipeline. 23 September 2021
Incyte Corp’s shares were down as much as 8.5% at $69.59 yesterday, despite the company receiving regulatory approval for a second drug within two days. 23 September 2021
Boston, USA-based Rhythm Pharmaceuticals has presented new data and analyses from Phase II and III trials of its candidate setmelanotide. 23 September 2021
Anglo-Swedish pharma major AstraZeneca has reached an agreement to collaborate with VaxEquity for the discovery, development and commercialization of the proprietary self-amplifying RNA (saRNA) therapeutics platform developed at Imperial College London. 23 September 2021
The HER2+ breast cancer market is expected to experience low growth from $10.4 billion in 2020 to $12.1 billion in 2030 across the eight major markets (8MM: the USA, France, Germany, Italy, Spain, UK, China and Japan) at a compound annual growth rate (CAGR) of 1.5%. 23 September 2021
US biotech Gilead Sciences (Nasdaq: GILD) has released positive results from a Phase III randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of Veklury (remdesivir) for intravenous (IV) use for the treatment of COVID-19 in non-hospitalized patients at high risk for disease progression. 23 September 2021
The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, today announced the launch of Opus Genetics, a patient-focused gene therapy company efficiently developing therapies for orphan inherited retinal diseases, based in Raleigh, North Carolina, USA. 22 September 2021